Visx' excimer laser gets approvable recommendation
This article was originally published in Clinica
Visx' (US) excimer laser system for photorefractive keratectomy received a conditional approval recommendation from the US FDA's ophthalmic devices advisory panel on October 20th. Panel members criticised the company for having incomplete patient follow-up and said they would not recommend approval until two-year follow-up included 90-95% of patients. Visx is seeking marketing approval for use of the laser in patients 18 years and older with -1.0 to -6.0 dioptre myopia with a best corrected vision of at least 20/40.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.